JP2011529912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529912A5 JP2011529912A5 JP2011521353A JP2011521353A JP2011529912A5 JP 2011529912 A5 JP2011529912 A5 JP 2011529912A5 JP 2011521353 A JP2011521353 A JP 2011521353A JP 2011521353 A JP2011521353 A JP 2011521353A JP 2011529912 A5 JP2011529912 A5 JP 2011529912A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- lipid
- cholesterol
- nanoparticle
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 claims 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 18
- 229940107161 Cholesterol Drugs 0.000 claims 11
- 229920000272 Oligonucleotide Polymers 0.000 claims 11
- 235000012000 cholesterol Nutrition 0.000 claims 11
- 150000002632 lipids Chemical class 0.000 claims 10
- -1 cationic lipid Chemical class 0.000 claims 9
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- 210000004027 cells Anatomy 0.000 claims 8
- 125000002091 cationic group Chemical group 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 210000001519 tissues Anatomy 0.000 claims 5
- 230000000692 anti-sense Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 230000000799 fusogenic Effects 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 229920002395 Aptamer Polymers 0.000 claims 2
- VODZWWMEJITOND-OWWNRXNESA-N N-Stearoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-OWWNRXNESA-N 0.000 claims 2
- 229920002224 Peptide nucleic acid Polymers 0.000 claims 2
- 229920001985 Small interfering RNA Polymers 0.000 claims 2
- RBAWEGYJSDPEHX-SNVBAGLBSA-N [(2R)-2,3-diformyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](OC=O)COC=O RBAWEGYJSDPEHX-SNVBAGLBSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229920001239 microRNA Polymers 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- 102100013894 BCL2 Human genes 0.000 claims 1
- 108060000885 BCL2 Proteins 0.000 claims 1
- 102100007326 BIRC5 Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 210000001956 EPC Anatomy 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 230000025458 RNA interference Effects 0.000 claims 1
- 229920001914 Ribonucleotide Polymers 0.000 claims 1
- 229920001385 Spiegelmer Polymers 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 102000015735 beta Catenin Human genes 0.000 claims 1
- 108060000903 beta Catenin Proteins 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002458 infectious Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 230000001023 pro-angiogenic Effects 0.000 claims 1
- 230000004647 pro-inflammatory pathway Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 229920002033 ribozyme Polymers 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
- 0 CC(*)(*)C(*)(*CCC1)C1(*)N(*)CCC* Chemical compound CC(*)(*)C(*)(*CCC1)C1(*)N(*)CCC* 0.000 description 5
- MZQUWCQHUCBQSW-UHFFFAOYSA-N IN1C(CCC2)N2CCC1 Chemical compound IN1C(CCC2)N2CCC1 MZQUWCQHUCBQSW-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8528908P | 2008-07-31 | 2008-07-31 | |
| US61/085,289 | 2008-07-31 | ||
| PCT/US2009/052396 WO2010014895A2 (fr) | 2008-07-31 | 2009-07-31 | Compositions de nanoparticules pour un système d'administration d'acides nucléiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529912A JP2011529912A (ja) | 2011-12-15 |
| JP2011529912A5 true JP2011529912A5 (fr) | 2012-07-26 |
Family
ID=41610973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521353A Pending JP2011529912A (ja) | 2008-07-31 | 2009-07-31 | 核酸送達システム用のナノ粒子組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110111044A1 (fr) |
| EP (1) | EP2304026A4 (fr) |
| JP (1) | JP2011529912A (fr) |
| CA (1) | CA2731173A1 (fr) |
| TW (1) | TW201004658A (fr) |
| WO (1) | WO2010014895A2 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962586B2 (en) * | 2010-02-22 | 2015-02-24 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1 |
| JP2013524811A (ja) | 2010-04-20 | 2013-06-20 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | ナノザイム、ナノザイムの製造方法、およびナノザイムの使用方法 |
| ES2770575T3 (es) | 2010-10-28 | 2020-07-02 | Pacira Pharmaceuticals Inc | Formulación de liberación sostenida de un fármaco antiinflamatorio no esteroideo |
| US8709466B2 (en) | 2011-03-31 | 2014-04-29 | International Business Machines Corporation | Cationic polymers for antimicrobial applications and delivery of bioactive materials |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| WO2013143555A1 (fr) | 2012-03-26 | 2013-10-03 | Biontech Ag | Formulation d'arn pour immunothérapie |
| WO2014070069A1 (fr) * | 2012-11-02 | 2014-05-08 | Telefonaktiebolaget L M Ericsson (Publ) | Noeud de réseau, noeud utilisateur et procédés d'évaluation de canal |
| JP6360074B2 (ja) * | 2013-01-03 | 2018-07-18 | カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ | マンノース受容体選択的リシニル化カチオン性両親媒性物質及びその調製方法 |
| US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
| WO2014144767A1 (fr) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Purification d'arnm par échange d'ions |
| EP2971165A4 (fr) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | Elimination de fragments d'adn dans des procédés de production d'arnm |
| EP3971287A1 (fr) | 2013-07-11 | 2022-03-23 | ModernaTX, Inc. | Compositions comprenant des polynucléotides synthétiques codant pour des protéines liées à crispr et des arnsg synthétiques et méthodes d'utilisation |
| CN104519875A (zh) | 2013-08-14 | 2015-04-15 | 佛罗里达大学研究基金会公司 | 纳米酶、制备纳米酶的方法、以及使用纳米酶的方法 |
| US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
| WO2015196128A2 (fr) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Molécules d'acide nucléique alternatives et leurs utilisations |
| JP2017522028A (ja) | 2014-07-16 | 2017-08-10 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 環状ポリヌクレオチド |
| WO2017049286A1 (fr) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucléotides contenant un lieur morpholino |
| CN112587504B (zh) * | 2016-10-17 | 2022-10-18 | 南京绿叶制药有限公司 | 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法 |
| CN109983013A (zh) | 2016-11-18 | 2019-07-05 | 帕西拉制药有限公司 | 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法 |
| EP3662913A4 (fr) * | 2017-08-04 | 2021-06-30 | Kyowa Kirin Co., Ltd. | Nanoparticules lipidiques contenant un acide nucléique |
| CA3088485A1 (fr) * | 2018-01-18 | 2019-07-25 | Etherna Immunotherapies Nv | Nanoparticules lipidiques |
| FI3864163T3 (fi) | 2018-10-09 | 2024-05-03 | Univ British Columbia | Koostumukset ja järjestelmät, joihin sisältyvät transfektiokompetentit vesikkelit, joissa ei ole orgaanisia liuottimia eikä pesuaineita, sekä niihin liittyvät menetelmät |
| CN109549934B (zh) * | 2018-12-25 | 2021-03-09 | 上海交通大学 | 一种多糖基脂质纳米粒子的制备方法 |
| JP2024521887A (ja) * | 2021-06-01 | 2024-06-04 | ナノベーション・セラピューティクス・インコーポレイテッド | 脂質ナノ粒子を用いるｄｎａベクター送達 |
| EP4248949A1 (fr) | 2022-03-21 | 2023-09-27 | R.G.C.C. Holdings AG | Compositions liposomales |
| WO2023178425A1 (fr) | 2022-03-23 | 2023-09-28 | Nanovation Therapeutics Inc. | Nanoparticules lipidiques à haute teneur en stérol |
| WO2023184038A1 (fr) * | 2022-04-01 | 2023-10-05 | Nanovation Therapeutics Inc. | Procédé d'administration d'arnm et composition associée |
| WO2024085149A1 (fr) * | 2022-10-18 | 2024-04-25 | 第一三共株式会社 | Réacteur de taylor et procédé de fabrication de particules de capsule |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| WO1997045069A1 (fr) * | 1996-05-29 | 1997-12-04 | Cell Genesys, Inc. | Polymeres/lipides cationiques servant de vehicules pour apporter de l'acide nucleique |
| EP1027033B1 (fr) * | 1997-05-14 | 2009-07-22 | The University Of British Columbia | Encapsulation hautement éfficace d'acides nucléiques dans des vésicules lipidiques |
| US6794499B2 (en) * | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6841537B1 (en) * | 1998-04-22 | 2005-01-11 | Protiva Biotherapeutics Inc. | Combination therapy using nucleic acids and conventional drugs |
| US20070042983A1 (en) * | 2001-05-18 | 2007-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20080207542A1 (en) * | 2002-03-26 | 2008-08-28 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| WO2006007712A1 (fr) * | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methodes permettant de distribuer des agents therapeutiques comprenant des conjugues de lipide-polyethylene glycol |
| CA2597724A1 (fr) * | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Compositions a base de nanoparticules lipidiques et methodes pour l'administration de molecules biologiquement actives |
| US7404969B2 (en) * | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| JP2009525055A (ja) * | 2006-02-01 | 2009-07-09 | ザ バーナム インスティテュート フォー メディカル リサーチ | 腫瘍および前癌性病変におけるリンパ管のジップコード |
| US20070293449A1 (en) * | 2006-06-20 | 2007-12-20 | Nastech Pharmaceutical Company Inc. | Compositions and methods for delivery of double-stranded rna |
| EP2076257A4 (fr) * | 2006-09-15 | 2014-04-16 | Belrose Pharma Inc | Conjugues polymeres contenant des fragments charges positivement |
-
2009
- 2009-07-31 WO PCT/US2009/052396 patent/WO2010014895A2/fr active Application Filing
- 2009-07-31 US US13/003,816 patent/US20110111044A1/en not_active Abandoned
- 2009-07-31 JP JP2011521353A patent/JP2011529912A/ja active Pending
- 2009-07-31 TW TW098125813A patent/TW201004658A/zh unknown
- 2009-07-31 CA CA2731173A patent/CA2731173A1/fr not_active Abandoned
- 2009-07-31 EP EP09803646.0A patent/EP2304026A4/fr not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529912A5 (fr) | ||
| Slaby et al. | Therapeutic targeting of non-coding RNAs in cancer | |
| JP2011520983A5 (fr) | ||
| JP5795072B2 (ja) | Ｒｎａ干渉を誘導する核酸分子及びその用途 | |
| JP2012509258A5 (fr) | ||
| EP2796150B1 (fr) | Nouveaux conjugués oligonucléotidiques et leur utilisation | |
| US9006191B2 (en) | Silencing of polo-like kinase expression using interfering RNA | |
| JP2012509272A5 (fr) | ||
| KR101752812B1 (ko) | 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법 | |
| JP2012509366A5 (fr) | ||
| JP2012509273A5 (fr) | ||
| JP2015518373A5 (fr) | ||
| JP2014530602A (ja) | アルデヒドデヒドロゲナーゼをサイレンシングするための組成物および方法 | |
| JP2015502365A5 (fr) | ||
| JP2011509258A5 (fr) | ||
| ES2809481T3 (es) | Estructura de oligonucleótidos de tipo nanopartícula mejorada que tiene alta eficiencia y método para preparar la misma | |
| WO2015082080A1 (fr) | Moyen de délivrance pulmonaire spécifique | |
| Bhavsar et al. | Translational siRNA therapeutics using liposomal carriers: prospects & challenges | |
| EP4183879A1 (fr) | Oligonucléotide double brin et composition pour le traitement de la covid-19 le contenant | |
| CN107630015B (zh) | 一种稳定的dna-rna双链结构 | |
| JP7208911B2 (ja) | 核酸分子発現の調節 | |
| WO2023168202A2 (fr) | Certains inhibiteurs dux4 et leurs procédés d'utilisation | |
| AU2013202970A1 (en) | Silencing of polo-like kinase expression using interfering RNA |